22 FEB. 2025
Generic CHO Platform
Choose the CHO expression system
For decades, the CHO (Chinese Hamster Ovary) expression system has proven to be a "Gold Standard" in the biopharmaceutical industry for its ability to ensure high-efficient, high-quality production of complex recombinant proteins.
Key efficiency arguments
♦ Efficiency and Productivity: CHO cells are capable of producing proteins at high titres, often between 5 and 10 g/L for an antibody (hIGg1) for example. As a model of an expression system in eukaryotic cells, the CHO lines derived from the original line characterised in the 1950s by Puck [1] are well documented.
With the proliferation of research on and use of CHO lines in bioproduction which has continued to accelerate since the 70s and 80s, the processes of transfection, clone selection and suspension culture are constantly being optimised.
♦ Quality and Safety: proteins produced by CHO cells have post-translational modifications similar to those of human proteins, thus ensuring high quality and optimal safety.
♦ Flexibility: the CHO system is suitable for the production of various types of proteins, including monoclonal antibodies, enzymes and hormones.
Would you like more information?
Focus on the CHO-S and CHO DG44 lines
For example, we use the CHO-S and DG44 cell lines, two of the most successful and widely used lines in the biopharmaceutical industry.
♦ CHO-S: this line is particularly appreciated for its ability to produce proteins at high levels in suspension. It was identified as a subclone of the K1 line, and was adapted specifically for suspensions as a derivative of the K1 line. It is a model of choice for cultures in bioreactors.
♦ DG44: This line is ideal for gene amplification and allows for high protein production yields. The selection and stability of the line have been optimised with the deletion of the 2 copies of the DHFR (Dihydrofolate Reductase) gene.
Our partnership with Sartorius gives us privileged access and allows for the sharing of skills in the implementation of this line from cell line development to implementation at the 2000 L scale.